| abstract |
The pathophysiology of cancer includes the action of matrix metalloproteinases (MMP) enzymes which enable the growth and spread of tumors both locally and as metastatic disease. In the present invention, these proteins are the target for inhibition employing in therapeutic administration phospholipase D inhibitor compounds, some potent compounds being short chain primary alcohols, in particular 1-butanol and 1-propanol. The anti-cancer action of these compounds derives from several pharmacological properties, including the ability to suppress phospholipase D, and both the intracellular and extracellular elaboration of MMP's. Thus disclosed herein are methods for treating a subject afflicted with a cell proliferative disorder, such as colorectal adenocarcinoma, malignant glioma, neuroblastoma, non-small cell lung carcinoma, and breast cancer, comprising the steps of administering an effective amount of 3 phospholipase D inhibitor to a subject in need of such treatment. In addition, provided herein are diagnostic methods for assessing disease activity and tissue sensitivity to treatment. |